GlassScriptPhysician profile
Rick T Bowers
NPI 1396784450
$182,258.60
in general payments reported to CMS, 2019-2025
29 companies · $1,017 in 2025
The $1,017 reported for 2025 was more than what 85% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58K · 2020: $16K · 2021: $34K · 2022: $48K · 2023: $16K · 2024: $8,973 · 2025: $1,017.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Food and Beverage: $7,910 · Travel and Lodging: $2,008 · Education: $47.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,575.00 |
| Food and Beverage | $7,909.63 |
| Travel and Lodging | $2,007.82 |
| Education | $47.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $108,324.00 | 2019-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $55,692.80 | 2021-2024 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $6,969.28 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Alkermes, INC. | $2,233.27 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $1,491.00 | 2019-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $1,299.80 | 2019-2024 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $915.52 | 2020-2025 | Caplyta |
| Abbvie INC. | $655.78 | 2021-2024 | Vraylar |
| Sunovion Pharmaceuticals INC. | $628.41 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $594.46 | 2019-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $594.28 | 2022-2025 | Auvelity |
| Corium, LLC | $538.65 | 2021-2024 | Azstarys |
| Lundbeck LLC | $497.99 | 2019-2025 | Rexulti, Abilify Maintena |
| E.R. Squibb & Sons, L.L.C. | $431.85 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $391.51 | 2019-2025 | Hetlioz, Fanapt |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $270.42 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $191.52 | 2020-2024 | Trintellix |
| Indivior INC. | $117.53 | 2020-2023 | Sublocade, Perseris |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $72.04 | 2023 | |
| Noven Therapeutics, LLC | $67.61 | 2021-2025 | Secuado |
| Idorsia Pharmaceuticals US INC | $65.90 | 2023 | Quviviq |
| Collegium Pharmaceutical, INC. | $47.49 | 2025 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $30.11 | 2023-2024 | Relexxii |
| Tempus Ai, INC | $29.91 | 2024 | |
| Tris Pharma INC | $28.62 | 2023 | Dyanavel Xr |
| Braeburn INC. | $25.83 | 2024 | Brixadi |
| Neuronetics, INC. | $21.59 | 2025 | Neurostar Tms Therapy System |
| Cognoa, INC. | $19.28 | 2022 | |
| Shire North American Group INC | $12.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rick Bowers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.